Login Register Cart 0
Generic placeholder image

Current Bioactive Compounds

Editor-in-Chief

ISSN (Print): 1573-4072
ISSN (Online): 1875-6646

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Improved Efficacy of Lovastatin from Soluplus-PEG Hybrid Polymer- Based Binary Dispersions

Author(s): Radhika Verma, Manju Nagpal*, Thakur G. Singh, Manjinder Singh and Geeta Aggarwal

Volume 16, Issue 8, 2020

Page: [1164 - 1171] Pages: 8

DOI: 10.2174/1573407216666191218142852

Price: $65

Abstract

Background: Lovastatin is a statin drug used for lowering cholesterol in those with hypercholesterolemia to reduce the risk of cardiovascular disease. It is a BCS class II drug i.e. it has low aqueous solubility and high permeability.

Objectives: Improvement of solubility and in vivo efficacy was investigated by formulating binary solid dispersions.

Methods: Binary solid dispersions of lovastatin were formulated in the current study using two polymers i.e. Soluplus and PEG 4000. Seven batches of solid dispersions were prepared (S1, P1, SP1, SP2, SP3, SP4, and SP5) via the solvent evaporation method. The prepared dispersions were evaluated for equilibrium solubility, FTIR, XRD, DSC, SEM studies, and further in vitro drug release were evaluated. The results revealed significant enhancement in the solubility of drug-using polymer hybrids as compared to that of individual polymer dispersion batches.

Results: A significant solubility enhancement was observed with SP5 (approx 40 times) having a higher concentration of Soluplus. FTIR studies indicated no drug to polymer interaction. DSC studies revealed complete amorphization of polymer and also X-RD data is also in compliance with DSC results. In vitro drug release studies showed almost 100% release in 2h in polymer hybrid batches in comparison to individual polymer batch (S1 and P1). The best dissolution characteristics were observed in SP3 and SP5 which is also in compliance with solubility data. Further in vivo efficacy studies revealed a significant reduction in LDL, HDL, TG, AST, and ALT levels in comparison to pure drug lovastatin group and hypercholesterolemia control group.

Conclusion: Hybrid polymer may be a prospective carrier system for the enhancement of solubility of BCS class II drugs.

Keywords: Hybrid, solubility, dissolution, hypolipidemic, soluplus, dispersions.

Graphical Abstract

[1]
Sareen, S.; Mathew, G.; Joseph, L. Improvement in solubility of poor water-soluble drugs by solid dispersion. Int. J. Pharm. Investig., 2012, 2(1), 12-17.
[http://dx.doi.org/10.4103/2230-973X.96921] [PMID: 23071955]
[2]
Maulvi, F.A.; Thakkar, V.T.; Soni, T.G.; Gandhi, T.R. Optimization of aceclofenac solid dispersion using Box-Behnken design: In-vitro and in-vivo evaluation. Curr. Drug Deliv., 2014, 11(3), 380-391.
[http://dx.doi.org/10.2174/1567201811666140311103425] [PMID: 24611664]
[3]
Huang, Y.; Dai, W.G. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm. Sin. B, 2014, 4(1), 18-25.
[http://dx.doi.org/10.1016/j.apsb.2013.11.001] [PMID: 26579360]
[4]
Sinha, S.; Ali, M.; Baboota, S.; Ahuja, A.; Kumar, A.; Ali, J. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech, 2010, 11(2), 518-527.
[http://dx.doi.org/10.1208/s12249-010-9404-1] [PMID: 20238187]
[5]
Vasconcelos, T.; Sarmento, B.; Costa, P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today, 2007, 12(23-24), 1068-1075.
[http://dx.doi.org/10.1016/j.drudis.2007.09.005] [PMID: 18061887]
[6]
Nagpal, M.; Raj, N.; Thakur, G.S.; Aggarwal, G. Improved solubility of itraconazole binary dispersions using neem gum: Development and characterization of topical gel. Curr. Bioact. Compd., 2019, 15(4), 399-407.
[http://dx.doi.org/10.2174/1573407214666180926120619]
[7]
Arunprasad, K.; Narayanan, N.; Rajalakshmi, G. Preparation and evaluation of solid dispersion of terbinafine hydrochloride. Int. J. Pharm. Sci. Rev. Res., 2010, 3(1), 130-134.
[8]
Djuris, J.; Nikolakakis, I.; Ibric, S.; Djuric, Z.; Kachrimanis, K. Preparation of carbamazepine-Soluplus solid dispersions by hot-melt extrusion, and prediction of drug-polymer miscibility by thermodynamic model fitting. Eur. J. Pharm. Biopharm., 2013, 84(1), 228-237.
[http://dx.doi.org/10.1016/j.ejpb.2012.12.018] [PMID: 23333900]
[9]
Lim, H.; Hoag, S.W. Plasticizer effects on physical-mechanical properties of solvent cast Soluplus® films. AAPS PharmSciTech, 2013, 14(3), 903-910.
[http://dx.doi.org/10.1208/s12249-013-9971-z] [PMID: 23689959]
[10]
Yadav, B.; Tanwar, Y.S. Applications of solid dispersions. J. Chem. Pharm. Res., 2015, 7(2), 965-978.
[11]
Hardung, H.; Djuric, D.; Ali, S. Combining HME solubilization: Soluplus®-the solid solution. Drug Deliv. Technol., 2010, 10(3), 20-27.
[12]
Hauss, D.J. Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs, 1st ed; CRC Press: New York, 2007.
[http://dx.doi.org/10.3109/9781420017267]
[13]
BASF. Technical Information Soluplus; BASF, 2010, pp. 1-8.
[14]
Lust, A.; Strachan, C.J.; Veski, P.; Aaltonen, J.; Heinämäki, J.; Yliruusi, J.; Kogermann, K. Amorphous solid dispersions of piroxicam and Soluplus(®): Qualitative and quantitative analysis of piroxicam recrystallization during storage. Int. J. Pharm., 2015, 486(1-2), 306-314.
[http://dx.doi.org/10.1016/j.ijpharm.2015.03.079] [PMID: 25843761]
[15]
Homayouni, A.; Sadeghi, F.; Varshosaz, J.; Afrasiabi Garekani, H.; Nokhodchi, A. Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques. Colloids Surf. B Biointerfaces, 2014, 122(122), 591-600.
[http://dx.doi.org/10.1016/j.colsurfb.2014.07.037] [PMID: 25124835]
[16]
Shamma, R.N.; Basha, M. Soluplus®: A novel polymeric solubilizer for optimization of Carvedilol solid dispersions: Formulation design and effect of method of preparation. Powder Technol., 2013, 2013(237), 406-414.
[http://dx.doi.org/10.1016/j.powtec.2012.12.038]
[17]
Han, S.D.; Jung, S.W.; Jang, S.W.; Jung, H.J.; Son, M.; Kim, B.M.; Kang, M.J. Preparation of solid dispersion of dronedarone hydrochloride with Soluplus(®) by hot melt extrusion technique for enhanced drug release. Chem. Pharm. Bull. (Tokyo), 2015, 63(4), 295-299.
[http://dx.doi.org/10.1248/cpb.c14-00725] [PMID: 25832024]
[18]
Fule, R.; Amin, P. Development and evaluation of lafutidine solid dispersion via hot melt extrusion: Investigating drug-polymer miscibility with advanced characterization. Asian J. Pharm. Sci., 2014, 9(2), 92-106.
[http://dx.doi.org/10.1016/j.ajps.2013.12.004]
[19]
Zhou, J.; Zhou, D. Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers. Drug Des. Devel. Ther., 2015, 9(9), 5269-5275.
[http://dx.doi.org/10.2147/DDDT.S90016] [PMID: 26425076]
[20]
Qureshi, M.J.; Mallikarjun, C.; Kian, W.G. Enhancement of solubility and therapeutic potential of poorly soluble lovastatin by SMEDDS formulation adsorbed on directly compressed spray dried magnesium aluminometasilicate liquid loadable tablets: A study in diet induced hyperlipidemic rabbits. Asian J. Pharm. Sci., 2015, 10(1), 40-56.
[http://dx.doi.org/10.1016/j.ajps.2014.08.003]
[21]
Priya, K.; Bhikshapathi, D.V.R.N. Development and in vivo evaluation of lovastatin by self-nanoemulsifying drug delivery system. Int. J. Pharm. Sci. Drug Res., 2018, 10(3), 165-172.
[22]
Patel, D.S.; Pipaliya, R.M.; Surti, N. Liquisolid tablets for dissolution enhancement of a hypolipidemic drug. Indian J. Pharm. Sci., 2015, 77(3), 290-298.
[http://dx.doi.org/10.4103/0250-474X.159618] [PMID: 26180274]
[23]
Mandal, S. Microemulsion drug delivery system: Design and development for oral bioavailability enhancement of lovastatin. S. Afr. Pharm. J., 2011, 78(3), 44-50.
[24]
Neduri, K.; Bontha, V.K.; Vemula, S.K. Different techniques to enhance the dissolution rate of lovastatin: Formulation and evaluation. Asian J. Pharm. Clin. Res., 2013, 6(1), 56-60.
[25]
Reginald-Opara, J.N.; Attama, A.; Ofokansi, K.; Umeyor, C.; Kenechukwu, F. Molecular interaction between glimepiride and Soluplus®-PEG 4000 hybrid based solid dispersions: Characterisation and anti-diabetic studies. Int. J. Pharm., 2015, 496(2), 741-750.
[http://dx.doi.org/10.1016/j.ijpharm.2015.11.007] [PMID: 26581773]
[26]
Sambath, L.; Muthu, A.K.; Kumar, M.A. Soluplus complexation influence the release of lovastatin from porous osmotic pump tablet. World J. Pharm. Pharm. Sci., 2013, 2(5), 3506-3521.
[27]
Arafa, H.M. Curcumin attenuates diet-induced hypercholesterolemia in rats. Med. Sci. Monit., 2005, 11(7), BR228-BR234.
[PMID: 15990684]
[28]
Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18(6), 499-502.
[http://dx.doi.org/10.1093/clinchem/18.6.499] [PMID: 4337382]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy